Inomata et al., found that CD4+PD-1+ T cell levels, but not CD8+PD1+ or CD8+CTLA-4+, predict longer PFS in non-small cell lung cancer patients undergoing different IC inhibitor treatments [51]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.